Nancy C. Andrews
Dr. Nancy C. Andrews is Dean Emerita and Professor of Pediatrics, Pharmacology and Cancer Biology, Duke University School of Medicine; and Vice Chancellor Emerita for Academic Affairs, Duke University. Prior to joining Duke she served as Director of the Harvard-MIT M.D.-Ph.D. program and was Dean for Basic Sciences and Graduate Studies and the George Richards Minot Professor of Pediatrics at the Harvard Medical School. From 1993 to 2006, Dr. Andrews was a biomedical research investigator of the Howard Hughes Medical Institute. Her research laboratory studied iron homeostasis and mouse models of human diseases. Over her research career, she provided critical insight into iron metabolism. Using molecular genetics, she identified proteins that regulate the absorption of dietary iron and transport of iron from the intestine to other cells. Andrews also characterized the role of the peptide hepcidin in redistributing iron in iron overload and inflammatory states, elucidating the pathophysiology of genetic hemochromatosis and the anemia of chronic disease. Dr. Andrews received her B.S. and M.S. in molecular biophysics and biochemistry from Yale University, her Ph.D. in biology from the Massachusetts Institute of Technology (MIT) and her M.D. from the Harvard Medical School. She completed her residency and fellowship training in pediatrics and hematology/oncology at the Children’s Hospital in Boston and the Dana-Farber Cancer Institute, and served as an attending physician at both institutions. Dr. Andrews served as president of the American Society of Clinical Investigation. She was elected as a Fellow of the American Association for the Advancement of Science and to membership in the National Academy of Sciences, the National Academy of Medicine and the American Academy of Arts and Sciences. She currently serves on the Council of the National Academy of Sciences, the Executive Committee of the MIT Corporation and on the Board of Directors of the American Academy of Arts and Sciences. She is also a member of the Boards of Directors of Novartis AG, Charles River Laboratories and Maze Therapeutics.